2. Signaling Pathways
  3. Immunology/Inflammation
  4. SphK
  5. SphK2 Isoform
  6. SphK2 Inhibitor

SphK2 Inhibitor

SphK2 Inhibitors (14):

Cat. No. Product Name Effect Purity
  • HY-15779A
    K145 hydrochloride
    		Inhibitor 99.63%
    K145 hydrochloride is a selective, substrate-competitive and orally active SphK2 inhibitor with an IC50 of 4.3 μM and a Ki of 6.4 μM. K145 hydrochloride is inactive against SphK1 and other protein kinases. K145 hydrochloride induces cell apoptosis and has potently antitumor activity.
  • HY-12892
    SKI-178
    		Inhibitor 99.29%
    SKI-178 is a potent sphingosine kinase-1 (SphK1) and SphK2 inhibitor. SKI-178 is cytotoxic at IC50 concentrations ranging from 1.8 to 0.1 μM in both agent sensitive and multi-agent resistant cancer cell lines (i.e., MTR3, NCI-ADR and HL60/VCR cells). SKI-178 induces apoptosis in a CDK1-dependent manner in human acute myeloid leukemia cell lines.
  • HY-147282
    Amgen-23
    		Inhibitor 98.11%
    Amgen-23 (compound 23) is a potent sphingosine kinases (SPHK) inhibitor with IC50 values of 20 nM and 1.6 μM for SPHK1 and SPHK2, respectively. Amgen-23 can be used for researching anticancer.
  • HY-120268A
    SLM6031434 hydrochloride
    		Inhibitor 99.1%
    SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD).
  • HY-148707
    SphK1&2-IN-1
    		Inhibitor 98.47%
    SphK1&2-IN-1 is a SphK inhibitor targeting to SphK1 and SphK2. SphK1&2-IN-1 has thermal stability.
  • HY-124368
    RB-042
    		Inhibitor
    RB-042 is a SK1 and SK2 inhibitor with IC50 values of 5.3 μM and 5.0 μM, respectively. RB-042 is applicable to the research of inflammatory diseases.
  • HY-12896
    SLR080811
    		Inhibitor
    SLR080811 is a guanidine-based selective sphingosine kinase 2 (SphK2) inhibitor with a Ki of 1.3 μM, exhibiting ~10-fold selectivity over SphK1 (Ki = 12 μM). SLR080811 reduces sphingosine 1-phosphate (S1P) levels in vitro, but drives a SphK1-dependent increase in S1P in mice. SLR080811 can be used for cancers and fibrosis research.
  • HY-12897
    (R)-FTY720-OMe
    		Inhibitor
    (R)-FTY720-OMe is a selective SphK2 inhibitor with an IC50 of 16.5  μM. (R)-FTY720-OMe can be used for cancer, fibrosis, and Alzheimer’s and sickle cell diseases research.
  • HY-151350
    SphK2-IN-1
    		Inhibitor 99.61%
    SphK2-IN-1 is a SphK2 inhibitor (IC50: 0.359 μM). SphK2-IN-1 can be used in the research of cancer, inflammation, neurological and cardiovascular disorders.
  • HY-150615
    SphK1-IN-2
    		Inhibitor
    SphK1-IN-2 is a potent, selective SphK1 inhibitor with IC50 values of 19.81 nM and ＞10 μM for SphK1 and SphK2, respectively. SphK1-IN-2 exhibits anti-proliferative activities and induces cell cycle arrest and apoptosis. SphK1-IN-2 can be used for cancer research.
  • HY-120268
    SLM6031434
    		Inhibitor
    SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD).
  • HY-112385
    ABC294735
    		Inhibitor
    ABC294735 is an orally active SK1/SK2 inhibitor. Combination of ABC294735 with Sorafenib (HY-10201) reduces pERK. ABC294735 exhibits anticancer activity against pancreatic adenocarcinoma and renal cell carcinoma. ABC294735 can be used in research related to pancreatic adenocarcinoma and renal cell carcinoma.
  • HY-183338
    SphK2-IN-4
    		Inhibitor
    SphK2-IN-4 is a selective SphK2 inhibitor (IC50=6.2 μM) with extremely low activity against SphK1 (IC50 > 50 μM). SphK2-IN-4 exhibits broad-spectrum antiproliferative activity against colorectal cancer cells and induces apoptosis.
  • HY-120440
    VT-ME6
    		Inhibitor
    VT-ME6 is a selective SphK2 inhibitor with a Ki of 8 µM. VT-ME6 can be used in the research of inflammatory diseases.